☆ 4.7 Meeting Abstract

First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3K delta) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 16, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

-

Categories

Oncology

Funding

  1. iOnctura SA

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.